Market Focus

means that our portfolio selection is focused on unmet market needs instead of platform technologies. We strive to bring first-in-class or best-in-class therapeutics that will offer meaningful and significant clinical benefits to patients who suffer from orphan diseases with few or no treatment options.

Science Driven

means that our portfolio selection is driven by scientific understanding of the disease pathology and therapeutic targets. Targeting the underlying genetic abnormality represents a mechanistically rational approach that would more likely reduce the development risk of our portfolio.

Strong Execution

means that we are leveraging our in-depth yet broad expertise in drug development to speed up the development of our portfolio towards global regulatory approval and commercialization.

Company Overview

Focus On First-in-class Or Best-in-class Therapeutics

Treating Orphan Diseases With Few or No Options.


Redwood City, CA, USA


Taipei, Taiwan